Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Daltex Medical Sciences

This article was originally published in The Gray Sheet

Executive Summary

Daltex Medical Sciences: Lowers the exercise price and extends the deadline to exercise its class A and B warrants. Effective Oct. 1, 1995, the Fairfield, New Jersey-based firm's class A warrants may be exercised for 25 [cents] a share (down from $3.25) until Dec. 31, 1995 (extended from Sept. 30, 1995). Effective April 1, 1996, class B warrants may be exercised for $3.25 per share (down from $5) until Dec. 31, 1996 (extended from March 31). In September 1994, Daltex extended the expiration dates of the class A and B warrants from Sept. 30, 1994 and March 31, 1995, respectively...

You may also be interested in...

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts